EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSOSIG00000007340
Gene Symbol: PIK3R3
1 Cross references
206 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSOSIG00000008879
Gene Symbol: PIK3R5
1 Cross references
200 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSOSIG00000017034
Gene Symbol: PIK3R5
1 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSOSIG00000009836
Gene Symbol: PIK3R1
1 Cross references
53 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSOSIG00000006372
Gene Symbol: PLA2G10
1 Cross references
232 Possible Orthologues:

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSOSIG00000020570
Gene Symbol: PLA2G7
1 Cross references
203 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSOSIG00000016693
Gene Symbol: PLAT
1 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSOSIG00000014609
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSOSIG00000020961
Gene Symbol: PDGFRB
1 Cross references
198 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSOSIG00000016380
Gene Symbol: PLK1
1 Cross references
188 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSOSIG00000018547
Gene Symbol: PARP2
1 Cross references
185 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSOSIG00000011027
Gene Symbol: PARP3
1 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).